Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 3Stomach Neoplasms 1Stereotactic Body Radiation Therapy 1Radiation Pneumonitis 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Brain Neoplasms 1Advanced Non-squamous Non-small Cell Lung Cancer 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 31Pemetrexed 28Radiotherapy 22Bevacizumab 21Cisplatin 20Gemcitabine 18Paclitaxel 17Erlotinib Hydrochloride 15Docetaxel 12Gefitinib 8Nivolumab 6Mastectomy, Segmental 6Magnetic Resonance Spectroscopy 6pembrolizumab 5aflutinib 5Radiosurgery 5tislelizumab 4Vinorelbine 4Surgical Procedures, Operative 4Specimen Handling 4Sorafenib 4Platinum 4Metformin 4Biopsy 42-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 4sargramostim 3apatinib 3Taxes 3Cetuximab 3Anterior Temporal Lobectomy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma of Lung × Angiogenesis Inhibitors × Clear all
NCT04459078 2022-12-02

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Hunan Cancer Hospital

Phase 2 Unknown
63 enrolled
Thoracic

Adenocarcinoma of Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡